trending Market Intelligence /marketintelligence/en/news-insights/trending/oCMqT-Z0UFq8jRqyXROeZg2 content esgSubNav
In This List

FibroGen appoints Lilly veteran as CEO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


FibroGen appoints Lilly veteran as CEO

FibroGen Inc. said its board appointed Enrique Conterno as CEO, replacing Jim Schoeneck.

Schoeneck became FibroGen's interim CEO after Thomas Neff, the company's chairman, founder and CEO, died in August 2019.

Conterno previously was the senior vice president at Eli Lilly and Co. and retired from the pharmaceutical giant at the end of 2019.

San Francisco-based FibroGen discovers, develops and commercializes treatments for chronic and life-threatening conditions such as anemia, idiopathic pulmonary fibrosis and pancreatic cancer.